Home Infusion for Lupus: Benlysta and Biologic Therapy Options for SLE

June 25, 2026

Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which the immune system generates antibodies that attack the body's own tissues, affecting the joints, skin, kidneys, heart, lungs, and nervous system. For patients with moderate-to-severe lupus that is inadequately controlled by conventional medications, IV biologic therapies offer a targeted approach to disease management.


For many lupus patients on stable biologic therapy, receiving these infusions through home infusion therapy is a clinically appropriate alternative to repeated infusion center visits. Pharmko coordinates lupus biologic infusions for patients and rheumatologists across 22+ states.


IV Biologic Therapies Used in Lupus


Benlysta (belimumab)


Benlysta is a monoclonal antibody that targets BLyS (B lymphocyte stimulator), a protein that supports the survival of autoreactive B cells, cells that produce the antibodies driving lupus inflammation and organ damage. By blocking BLyS, Benlysta reduces the number and activity of these harmful B cells, lowering disease activity and reducing flare frequency.

Benlysta is FDA-approved for active, autoantibody-positive SLE in adults and for active lupus nephritis. It is available in two formulations: IV infusion (given monthly after loading doses at weeks 0, 2, and 4) and subcutaneous injection (given weekly). The IV formulation is administered over one hour and is the standard route for patients initiating therapy or who prefer monthly dosing over weekly self-injection.


Saphnelo (anifrolumab)


Saphnelo is a newer IV biologic approved in 2021 for moderate-to-severe SLE in adults on standard therapy. It blocks the type I interferon receptor, a signaling pathway overactivated in many lupus patients and associated with disease flares and organ damage. Saphnelo is administered by IV infusion every 4 weeks over 30 minutes.


Because Saphnelo is relatively new, fewer patients have transitioned to home infusion compared to Benlysta, but it is appropriate for home administration in stable patients following the same criteria as other IV biologics.


IVIG in Lupus


Intravenous immunoglobulin (IVIG) is used off-label in certain severe manifestations of lupus, including thrombocytopenia, hemolytic anemia, and neuropsychiatric lupus, typically as a bridge therapy or when conventional immunosuppressants are contraindicated. It is not a first-line treatment for SLE but plays a role in acute flare management.


Who Qualifies for Home Infusion of Lupus Biologics?


Home infusion of IV lupus biologics is appropriate for patients who:


  • Have received their initial loading doses (weeks 0, 2, and 4 for Benlysta) in a supervised clinical setting without significant infusion reactions
  • Are on a stable, maintenance dosing schedule
  • Have been assessed by their rheumatologist as clinically stable for home-based administration
  • Have lupus nephritis or other organ involvement that is being actively monitored but does not require inpatient care


Patients with active lupus flares, new organ involvement, or recent serious infections typically require physician-supervised infusions until their clinical situation is stabilized.


What to Expect During a Home Lupus Infusion


Before the infusion


A Pharmko nurse reviews your current medications, confirms the absence of active infection, checks vital signs, and prepares the medication. Pre-medications may be administered per your rheumatologist's orders.


During the infusion


Benlysta infusions run over one hour; Saphnelo over 30 minutes. Your nurse monitors your vital signs throughout and is present to respond to any reaction. The infusion rate may be slowed if you experience nausea, headache, or other mild symptoms.


After the infusion


Your nurse documents the session and communicates with your rheumatologist's office. Know which symptoms require an immediate call in the hours following your infusion, including fever, chest tightness, or new joint swelling, and save our after-hours support number before your first home dose.

Lupus and the Broader Autoimmune Infusion Landscape


Lupus patients may also have overlapping conditions, particularly Sjögren's syndrome, antiphospholipid syndrome, or lupus nephritis, that introduce additional treatment considerations. For patients managing multiple autoimmune conditions treated with IV biologics, our guide on home infusion for autoimmune diseases provides a broader overview of how these therapies are coordinated. For Crohn's disease specifically, which shares some biologic treatment pathways, see our guide on home infusion for Crohn's disease.


Insurance Coverage for Lupus Biologic Infusions


Benlysta and Saphnelo are covered under the medical benefit by Medicare Part B and most commercial insurance plans when administered by a licensed provider to patients with documented active, autoantibody-positive SLE. Prior authorization is required and must include lab documentation of autoantibody positivity and evidence of inadequate response to standard therapy. Pharmko manages the full authorization process and communicates any coverage issues before your first home infusion.


Contact Pharmko to start a lupus infusion referral: 1-877-540-2003


July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More